At a glance
- Originator Agouron Pharmaceuticals; University of Newcastle upon Tyne
- Developer University of Newcastle upon Tyne
- Class Antineoplastics; Quinazolines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer